These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1031 related articles for article (PubMed ID: 9181234)

  • 1. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
    Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
    Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
    Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
    Shiloni E; Karp SE; Custer MC; Shilyansky J; Restifo NP; Rosenberg SA; Mulé JJ
    Cancer Immunol Immunother; 1993 Oct; 37(5):286-92. PubMed ID: 8402732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.
    Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF
    Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
    Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
    Tuttle TM; Inge TH; Lind DS; Bear HD
    Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.